- Home
- GENK vs SLGL Comparison
GENK vs SLGL Comparison
Compare GENK & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENK
- SLGL
- Stock Information
- Founded
- GENK 2011
- SLGL 1997
- Country
- GENK United States
- SLGL Israel
- Employees
- GENK N/A
- SLGL N/A
- Industry
- GENK Restaurants
- SLGL Biotechnology: Pharmaceutical Preparations
- Sector
- GENK Consumer Discretionary
- SLGL Health Care
- Exchange
- GENK Nasdaq
- SLGL Nasdaq
- Market Cap
- GENK 20.4M
- SLGL 19.3M
- IPO Year
- GENK 2023
- SLGL 2018
- Fundamental
- Price
- GENK $3.81
- SLGL $8.14
- Analyst Decision
- GENK Strong Buy
- SLGL Buy
- Analyst Count
- GENK 2
- SLGL 1
- Target Price
- GENK $10.00
- SLGL $40.00
- AVG Volume (30 Days)
- GENK 46.6K
- SLGL 25.4K
- Earning Date
- GENK 07-30-2025
- SLGL 08-15-2025
- Dividend Yield
- GENK 0.79%
- SLGL N/A
- EPS Growth
- GENK N/A
- SLGL N/A
- EPS
- GENK N/A
- SLGL N/A
- Revenue
- GENK $214,957,000.00
- SLGL $12,103,000.00
- Revenue This Year
- GENK $17.79
- SLGL N/A
- Revenue Next Year
- GENK $15.87
- SLGL $31.17
- P/E Ratio
- GENK N/A
- SLGL N/A
- Revenue Growth
- GENK 14.40
- SLGL 603.66
- 52 Week Low
- GENK $3.16
- SLGL $3.34
- 52 Week High
- GENK $10.33
- SLGL $16.50
- Technical
- Relative Strength Index (RSI)
- GENK 47.86
- SLGL 63.80
- Support Level
- GENK $3.72
- SLGL $6.96
- Resistance Level
- GENK $3.98
- SLGL $7.48
- Average True Range (ATR)
- GENK 0.22
- SLGL 0.28
- MACD
- GENK 0.02
- SLGL 0.07
- Stochastic Oscillator
- GENK 51.36
- SLGL 95.88
About GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. It operates 43 Gen Korean BBQ restaurants in the United States.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.